Abstract
Although common in patients with PHN (>50%), dynamic allodynia has not been routinely evaluated in large RCTs. We evaluated the effect of pregabalin, an alpha-2-delta ligand, on Visual Analog Scale (VAS) ratings of dynamic (brush-evoked) allodynia in PHN in this placebo-controlled RCT. The study consisted of a 7-day screening period, 28-day treatment phase, and 1-week taper. Patients (≥18y) with PHN for 3 months, pain VAS score of 40mm (100-mm scale), who completed the daily pain NRS ≥4 times (average daily score 4; 0-10 scale) during 7-day screening.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call